ReviewThe Journal of international medical research2026
Third-generation sequencing technology in the prevention and control of thalassemia: Applications and advances.
Review in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapid advancement of sequencing technology, third-generation sequencing, particularly single-molecule real-time sequencing and nanopore sequencing, has opened new avenues for the precise prevention and control of genetic diseases. It offers distinct advantages, including long-read lengths, minimal requirement for extensive polymerase chain reaction amplification, and real-time sequencing capability. This narrative review summarizes and critically evaluates recent advances in the application and latest progress of third-generation sequencing in thalassemia. It focuses on the technical advantages and application status of this technology in detecting complex structural variations, large-scale carrier screening, prenatal diagnosis, and preimplantation genetic testing. The review further analyzes the considerable potential of this technology in improving diagnostic accuracy, shortening detection cycles, and reducing technical costs. Additionally, it discusses the challenges currently faced in data interpretation, standardized processes, and clinical translation. Finally, this review provides insights into future development directions, with the aim of providing new technical perspectives and a theoretical basis for optimizing the prevention and control strategies of thalassemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.